<DOC>
	<DOC>NCT02675855</DOC>
	<brief_summary>The objective of the study is to compare the efficacy of weekly GrafixPRIME® administration to an Active Comparator in patients with chronic DFUs in a randomized, single-blind study.</brief_summary>
	<brief_title>GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Type 1 or Type 2 Diabetes Chronic ulcer (present for ≥4 weeks, but not more than 52 weeks) Index ulcer located below the malleoli on the plantar or dorsal surface of the foot Index ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone or joint capsule Adequate circulation to the foot (documented by ABI or TBI) Gangrene present on affected foot Index ulcer is over a Charcot deformity Patient is receiving dialysis Patient has 2 or more previous amputations Patient has HbA1c &gt;12% or random blood sugar &gt;450 mg/dl Chronic oral steroid use Use of IV corticosteroid, immunosuppressive, or cytotoxic agents IV antibiotics Another ulcer within 5cm of the Index ulcer Cellulitis, evidence of infection, or osteomyelitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Grafix</keyword>
</DOC>